|Mr. Emil Billbäck||Chief Exec. Officer||5.07M||N/A||1970|
|Prof. Lars A. Lidgren M.D., Ph.D.||Founder & Director||149k||N/A||1943|
|Mr. Håkan Johansson||Chief Financial Officer||N/A||N/A||1963|
|Ms. Ann-Marie Thor||Acting Exec. VP of Global Marketing||N/A||N/A||N/A|
|Ms. Helena L. Brandt||Head of HR||N/A||N/A||1965|
|Dr. Michael Diefenbeck M.D., Ph.D.||Exec. VP of Medical & Clinical Affairs and Chief Medical Officer||N/A||N/A||1974|
|Dr. Jerry Chang||Exec. VP of R&D, Regulatory and Clinical||N/A||N/A||1959|
|Mr. Fergus MacLeod||GM & Exec. VP of Commercial Operations of EUROW||N/A||N/A||1970|
|Ms. Kristina Ingvar||Exec. VP of Quality Management & Regulatory Affairs||N/A||N/A||1972|
|Mr. Michael Roth||GM & Exec. VP of Commercial Operations of North America||N/A||N/A||1963|
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
Bonesupport Holding AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.